**Supplementary Table ST1. Comparison of survival models in all patients**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | AIC | | BIC | |
|  | serplulimab group | Chemotherapy group | serplulimab group | Chemotherapy |
| PFS |  |  |  |  |
| Weibull | 1436.440 | 742.686 | 1444.257 | 749.105 |
| **Log-logistic** | **1412.581** | **718.606** | **1420.398** | **725.025** |
| Log-normal | 1417.510 | 728.866 | 1425.326 | 735.258 |
| Gompertz | 1452.733 | 763.516 | 1460.549 | 769.935 |
| Exponential | 1451.711 | 763.301 | 1455.619 | 766.510 |
| Gamma | 1429.093 | 733.209 | 1436.909 | 739.628 |
| OS |  |  |  |  |
| Weibull | 1342.362 | 769.800 | 1350.178 | 776.219 |
| **Log-logistic** | **1335.763** | **767.748** | **1343.579** | **774.167** |
| Log-normal | 1338.866 | 768.784 | 1346.682 | 775.203 |
| Gompertz | 1359.129 | 780.649 | 1366.945 | 787.068 |
| Exponential | 1370.678 | 794.387 | 1374.586 | 797.596 |
| Gamma | 1338.795 | 767.495 | 1346.611 | 773.914 |

AIC: Akaike information criterion; BIC: Bayesian Information Criterion; OS: Overall survival; PFS: Progression-free survival;